Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergio Fazio

Showing results (41-50 of 284) with videos related to

Pageof 29
Sort By:
Circulation Research|July 9, 2013
Killing two birds with one stone, maybe: CETP inhibition increases both high-density lipoprotein levels and insulin secretionSergio Fazio, MacRae F Linton
Journal of Diabetes|July 3, 2018
Medication-based versus target-based lipid managementSergio Fazio, Michael D Shapiro
Nature Reviews. Cardiology|May 5, 2017
Dyslipidaemia: The PCSK9 adventure - humanizing extreme LDL loweringMichael D Shapiro, Sergio Fazio
Drug Discovery Today. Therapeutic Strategies|April 4, 2009
Cyclooxygenase products and atherosclerosisMacrae F Linton, Sergio Fazio
Journal of the American College of Cardiology|February 15, 2020
Aggressive Treatment for Severe Forms of Familial HypercholesterolemiaP Barton Duell, Sergio Fazio
European Journal of Preventive Cardiology|September 11, 2018
Biologic bases of residual risk of cardiovascular events: A flawed conceptMichael D Shapiro, Sergio Fazio
American Journal of Preventive Cardiology|August 25, 2020
The American journal of preventive cardiology: On a mission to help define a specialtySergio Fazio, Nathan D Wong
Archives of Medical Research|May 27, 2015
Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density LipoproteinValentina Kon, Haichun Yang, Sergio Fazio
Current Opinion in Endocrinology, Diabetes, and Obesity|February 19, 2015
PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9Hagai Tavori, Ilaria Giunzioni, Sergio Fazio
Atherosclerosis|December 30, 2014
On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effectsHagai Tavori, Shirya Rashid, Sergio Fazio
Pageof 29

Showing results (41-50 of 284) with videos related to

Sort By:
Pageof 29
Circulation Research|July 9, 2013
Killing two birds with one stone, maybe: CETP inhibition increases both high-density lipoprotein levels and insulin secretionSergio Fazio, MacRae F Linton
Journal of Diabetes|July 3, 2018
Medication-based versus target-based lipid managementSergio Fazio, Michael D Shapiro
Nature Reviews. Cardiology|May 5, 2017
Dyslipidaemia: The PCSK9 adventure - humanizing extreme LDL loweringMichael D Shapiro, Sergio Fazio
Drug Discovery Today. Therapeutic Strategies|April 4, 2009
Cyclooxygenase products and atherosclerosisMacrae F Linton, Sergio Fazio
Journal of the American College of Cardiology|February 15, 2020
Aggressive Treatment for Severe Forms of Familial HypercholesterolemiaP Barton Duell, Sergio Fazio
European Journal of Preventive Cardiology|September 11, 2018
Biologic bases of residual risk of cardiovascular events: A flawed conceptMichael D Shapiro, Sergio Fazio
American Journal of Preventive Cardiology|August 25, 2020
The American journal of preventive cardiology: On a mission to help define a specialtySergio Fazio, Nathan D Wong
Archives of Medical Research|May 27, 2015
Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density LipoproteinValentina Kon, Haichun Yang, Sergio Fazio
Current Opinion in Endocrinology, Diabetes, and Obesity|February 19, 2015
PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9Hagai Tavori, Ilaria Giunzioni, Sergio Fazio
Atherosclerosis|December 30, 2014
On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effectsHagai Tavori, Shirya Rashid, Sergio Fazio
Pageof 29